Back to Journals » International Journal of Nanomedicine » Volume 11

Silver nanoparticles outperform gold nanoparticles in radiosensitizing U251 cells in vitro and in an intracranial mouse model of glioma

Authors Liu PD, Jin H, Guo Z, Ma J, Zhao J, Li D, Wu H, Gu N

Received 21 June 2016

Accepted for publication 8 August 2016

Published 3 October 2016 Volume 2016:11 Pages 5003—5014


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Lei Yang

Peidang Liu,1,2 Haizhen Jin,1 Zhirui Guo,3 Jun Ma,4 Jing Zhao,1 Dongdong Li,1 Hao Wu,2 Ning Gu2

1School of Medicine, 2State Key Laboratory of Bioelectronics, Jiangsu Key Laboratory for Biomaterials and Devices, Southeast University, 3The Second Affiliated Hospital of Nanjing Medical University, 4Traditional Chinese Medicine Hospital of Jiangsu Province, Nanjing, People’s Republic of China

Abstract: Radiotherapy performs an important function in the treatment of cancer, but resistance of tumor cells to radiation still remains a serious concern. More research on more effective radiosensitizers is urgently needed to overcome such resistance and thereby improve the treatment outcome. The goal of this study was to evaluate and compare the radiosensitizing efficacies of gold nanoparticles (AuNPs) and silver nanoparticles (AgNPs) on glioma at clinically relevant megavoltage energies. Both AuNPs and AgNPs potentiated the in vitro and in vivo antiglioma effects of radiation. AgNPs showed more powerful radiosensitizing ability than AuNPs at the same mass and molar concentrations, leading to a higher rate of apoptotic cell death. Furthermore, the combination of AgNPs with radiation significantly increased the levels of autophagy as compared with AuNPs plus radiation. These findings suggest the potential application of AgNPs as a highly effective nano-radiosensitizer for the treatment of glioma.

Keywords: gold nanoparticles, silver nanoparticles, radiosensitization, glioma, apoptosis, autophagy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]